Ocugen, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.7027 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 238.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Details
| Name | Ocugen, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 116 |
| Founded | 2013 |
| Ceo | Shankar Musunuri |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US67577C1053 |
| Cusip | 67577C105 |
| Cik | 1372299 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research and Development |
| Rita Johnson-Greene M.B.A. | Chief Financial Officer and Principal Accounting Officer |
| Paul Staid | Executive Vice President of Operations |
| John Kouch J.D. | General Counsel |
| Chris Clark | Vice President of Corporate Communications |
| Kristen Craft | Head of People and Culture |
| Dr. Vijay Tammara Ph.D. | Chief Development Officer |
| Dr. Mohamed Genead M.D., M.Sc. | Chief Medical Officer |
| Jyothy Pillai M.S. | Vice President and Head of Regulatory & Quality |
Contact
| Address | 11 Great Valley Parkway, Malvern, Pennsylvania 19355, United States |
| Phone | 484 328 4701 |
| Website | https://www.ocugen.com |